Literature DB >> 29341116

Rare missense mutations in RECQL and POLG associate with inherited predisposition to breast cancer.

Anna Tervasmäki1, Tuomo Mantere1, Jaana M Hartikainen2,3, Saila Kauppila4, Hang-Mao Lee5, Susanna Koivuluoma1, Mervi Grip6, Peeter Karihtala7, Arja Jukkola-Vuorinen7, Arto Mannermaa2,3, Robert Winqvist1, Katri Pylkäs1.   

Abstract

Several known breast cancer susceptibility genes with moderate-to-high risk alleles encode proteins involved in DNA damage response (DDR). As these explain less than half of the hereditary breast cancer cases, additional predisposing alleles are likely to be discovered. Many of the previous studies utilizing massive parallel sequencing have focused on the protein-truncating variants, and the role of rare missense mutations has remained poorly addressed. To identify novel susceptibility factors, we have systematically analyzed the data from our parallel sequencing of 796 DDR genes in 189 Northern Finnish hereditary breast cancer patients for rare missense variants, predicted as deleterious. Thirty-five variants were studied here for the disease association using Finnish breast cancer case (n = 492-2,035) and control (n = 277-1,539) cohorts. As a result, two missense variants in genes involved in DNA replication, RECQL p.I156M and POLG p.L392V, the former involving genomic and the latter mitochondrial DNA replication, showed significant association with risk of breast cancer. Rare RECQL p.I156M allele was observed in breast cancer cases only (6/1,946, 0.3%, p = 0.043), whereas POLG p.L392V was two times more frequent in breast cancer cases (53/2,238, 2.4%) compared to controls (18/1,539, 1.2%, OR = 2.1, 95% CI 1.2-3.5, p = 0.010). Based on the current genetic data, both RECQL p.I156M and POLG p.L392V represent novel breast cancer predisposing alleles.
© 2018 UICC.

Entities:  

Keywords:  DNA damage response pathway; POLG; RECQL; breast cancer; genetic susceptibility; missense mutations

Mesh:

Substances:

Year:  2018        PMID: 29341116     DOI: 10.1002/ijc.31259

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Pathogenic Germline Mutations in DNA Repair Genes in Combination With Cancer Treatment Exposures and Risk of Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer.

Authors:  Na Qin; Zhaoming Wang; Qi Liu; Nan Song; Carmen L Wilson; Matthew J Ehrhardt; Kyla Shelton; John Easton; Heather Mulder; Dennis Kennetz; Michael N Edmonson; Michael C Rusch; James R Downing; Melissa M Hudson; Kim E Nichols; Jinghui Zhang; Leslie L Robison; Yutaka Yasui
Journal:  J Clin Oncol       Date:  2020-06-04       Impact factor: 44.544

Review 2.  RecQ Helicase Somatic Alterations in Cancer.

Authors:  Megha K Thakkar; Jamie Lee; Stefan Meyer; Vivian Y Chang
Journal:  Front Mol Biosci       Date:  2022-06-15

3.  High Expression of RECQL Protein in ER-Positive Breast Tumours Is Associated With a Better Survival.

Authors:  Ardalan Mahmoodi; Ahmed Shoqafi; Ping Sun; Vasily Giannakeas; Cezary Cybulski; Sharon Nofech-Mozes; Jean-Yves Masson; Sudha Sharma; Amir Abbas Samani; Srinivasan Madhusudan; Steven A Narod; Mohammad R Akbari
Journal:  Front Oncol       Date:  2022-05-31       Impact factor: 5.738

Review 4.  Human RecQ Helicases in DNA Double-Strand Break Repair.

Authors:  Huiming Lu; Anthony J Davis
Journal:  Front Cell Dev Biol       Date:  2021-02-25

Review 5.  Deoxyribonucleotide Triphosphate Metabolism in Cancer and Metabolic Disease.

Authors:  Raquel Buj; Katherine M Aird
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-18       Impact factor: 5.555

6.  PolG Inhibits Gastric Cancer Glycolysis and Viability by Suppressing PKM2 Phosphorylation.

Authors:  Mengzhu Lv; Simeng Zhang; Yuqing Dong; Liu Cao; Shu Guo
Journal:  Cancer Manag Res       Date:  2021-02-16       Impact factor: 3.989

Review 7.  RECQ1 Helicase in Genomic Stability and Cancer.

Authors:  Subrata Debnath; Sudha Sharma
Journal:  Genes (Basel)       Date:  2020-06-05       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.